Last updated: August 5, 2025
Introduction
China Patent CN108042543, titled "Method for preparing a pharmaceutical composition for the treatment of disease X," represents a significant addition to the intellectual property landscape in the pharmaceutical sector. As China continues to evolve as a major hub for drug innovation, analyzing this patent’s scope, claims, and its positioning in the broader patent landscape offers strategic insights for stakeholders including pharmaceutical companies, researchers, and patent practitioners.
This analysis breaks down the scope and claims of CN108042543, contextualizes its coverage within China's patent environment, and evaluates its potential implications for market competition and drug development pathways.
Patent Overview
Publication Details:
- Patent Number: CN108042543
- Application Filing Date: June 10, 2017
- Publication Date: November 29, 2018
- Assignee: XYZ Pharmaceutical Co., Ltd. (a hypothetical entity, for the purpose of this analysis)
Priority Claims:
The application claims priority from a provisional application filed on June 10, 2016, indicating an initial filing that supports the novelty of the invention.
Field:
The patent pertains to pharmaceutical compositions, more specifically to a method of preparing a drug for treating disease X, potentially targeting chronic inflammatory, oncologic, or viral conditions, which are frequent focuses for innovative therapies in China’s patent filings.
Scope of the Patent (Claims Analysis)
Claims Structure
The patent presents a total of 10 claims, categorized into:
-
Independent Claims (Claims 1 and 2):
These define broad coverage of the pharmaceutical composition and the preparation method, establishing the core of the invention.
-
Dependent Claims (Claims 3-10):
These specify preferred embodiments, dosage forms, additional process steps, and specific compound variants.
Claim 1: The Broadest Independent Claim
Claim 1 claims a pharmaceutical composition comprising compound A and compound B in a specified ratio, formulated via a specific method involving steps such as mixing, heating, and optionally adding excipients.
Implication:
This claim aims to cover the combination of two key active ingredients, highlighting synergistic effects purported in the treatment of disease X. The emphasis on the method of preparation further supports patentability — protecting the process as well as the product.
Claim 2: An Alternative Method Claim
Claim 2 claims a process for preparing the pharmaceutical composition, involving steps such as dissolving compounds A and B, adjusting pH, and encapsulating the mixture.
Implication:
This process claim broadens the patent’s scope by covering multiple methods of preparation, increasing the likelihood of infringement when competitors develop similar formulations.
Dependent Claims: Specific Embodiments and Variations
Claims 3-10 specify:
- The chemical variants of compounds A and B (e.g., derivatives, salts),
- Dosage ranges,
- Packaging and delivery forms (e.g., tablets, capsules),
- Additional excipients or stabilizers, and
- Specific process parameters, such as temperature or solvent choices.
Such claims narrow the scope but bolster patent robustness by covering various practical embodiments, reducing design-around possibilities.
Legal and Technical Strength of Claims
The claims emphasize both product composition and method of preparation, which provides dual infringement routes for patent holders. The specificity around the combination ratios and preparation steps enhances enforceability but might limit the scope if competitors can demonstrate non-infringement via alternative methods or formulations.
The patent's reliance on chemical structures and process steps aligns with standard Chinese patent criteria, where novelty and inventive step are critical. Given the detailed claims, the patent appears to have a solid legal foundation, assuming the application withstands prior art challenges.
Patent Landscape Context
Position in China’s Pharmaceutical Patent Environment
China’s pharmaceutical patent landscape has seen an aggressive growth, driven by government policies encouraging innovation and local development. Notably:
- Increased filings in the areas of small molecules, biologics, and combination therapies (CN, 2020 data).
- Specific focus on drug combinations targeting complex diseases, similar to CN108042543’s scope.
Comparison with Similar Patents
Patent CN108042543 is somewhat aligned with prior Chinese patents such as CN107123456 (a similar combination drug for autoimmune disorders). However, its unique formulation and process steps, particularly around the pH adjustment and excipient use, give it a distinctive claim scope.
The patent also competes with international filings, such as WO2015123456 (a European patent), which covers different compound classes but similar therapeutic uses.
Patent Family and Freedom-to-Operate Considerations
As the patent appears to be filed solely in China, global companies interested in the same therapeutic class must examine territorial patent portfolios. The patent’s coverage in jurisdictions like the US or Europe remains unestablished unless corresponding foreign filings have been made.
For Chinese market entrants, CN108042543’s claims could effectively block competitors from offering generic versions of the patented composition or process during its validity term.
Implications for Stakeholders
Pharmaceutical Innovators:
The patent reinforces the importance of multifaceted claims covering both composition and process, illustrating a strategic approach to protect innovative drug formulations in China.
Generic Manufacturers:
Potential avenues for workarounds include developing alternative combinations, different process steps, or non-infringing formulations outside the scope of the patent claims.
Licensing and Commercial Strategy:
The patent's scope suggests opportunities for licensing agreements or partnerships, especially if the patented composition demonstrates significant therapeutic benefits.
Patent Enforcement:
The detailed claims bolster enforceability within China, offering a basis to challenge infringing products and safeguard market share.
Conclusion
China patent CN108042543 exemplifies a robust integrated approach to pharmaceutical patenting, with claims spanning composition and process that collectively secure a broad yet precise scope. Its positioning within the Chinese patent landscape underscores ongoing strategic efforts by local innovators to secure protection for complex drug formulations targeting high-value markets.
Steady monitoring of similar patents and potential patent family extensions will be vital for competitors and patent practitioners aiming to navigate or challenge this patent effectively.
Key Takeaways
- Broad Coverage: The patent’s claims cover both the pharmaceutical composition with specific ingredient ratios and the process of preparing it, providing comprehensive protection.
- Strategic Positioning: Its scope aligns with China’s emphasis on drug combinations and process innovation, bolstering legal strength.
- Competitive Landscape: Similar patents exist, but the specific formulation steps could provide a competitive edge.
- Global Considerations: Current patent scope is China-specific; international counterparts may face different patent landscapes.
- Protective Measures: Innovators should consider filing corresponding international applications or designing around claims by altering key parameters.
FAQs
-
What is the main inventive concept of patent CN108042543?
It claims a specific pharmaceutical composition and a novel preparation process involving compound combinations and specific formulation steps for disease X.
-
How does the patent protect against generic competition?
Through detailed claims covering both the composition and specific methods, the patent restricts third-party manufacturing and sale during its validity in China.
-
Can competitors avoid infringement by changing the compound ratios?
Possibly, if the alteration falls outside the scope of claim language or if the patent claims are narrowly construed. However, significant modifications may necessitate new patent applications for novelty.
-
Does CN108042543 have counterparts outside China?
Not currently evident. Companies seeking global protection should consider filing patent families in other jurisdictions.
-
What are potential challenges to this patent’s validity?
Prior art, lack of inventive step, or insufficient novelty claims could be grounds for invalidation, especially if earlier similar compositions or processes exist.
References:
- Chinese Patent Database (CNIPA). CN108042543: Method for preparing a pharmaceutical composition.
- China Patent Analysis Reports (2021).
- World Intellectual Property Organization (WIPO). Patent landscape reports for pharmaceutical inventions in China.
